v3.26.1
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Schedule of Segment Reporting The following table represents information provided to the CODM:
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Research and development expenses:
Wages and benefits$3,221 $1,794 $5,825 $3,261 
Tibulizumab SSc program4,209 1,430 7,409 4,196 
Tibulizumab HS program4,688 2,000 9,389 3,274 
Tibulizumab program general6,929 2,167 9,858 5,871 
Additional product candidates (torudokimab and crebankitug)176 460 347 751 
Unallocated research and development expenses469 476 1,042 931 
General and administrative expenses:
Wages and benefits1,992 2,792 4,678 5,383 
Other general and administrative expenses3,163 3,198 6,775 6,251 
Stock-based compensation4,457 3,732 9,465 7,376 
Other segment items*(3,000)(2,056)(4,261)(3,859)
Net loss$26,304 $15,993 $50,527 $33,435 
*Other segment items include depreciation and amortization, income tax benefit, interest income, and other income net.
Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Share because to do so would be Anti-dilutive
The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as of the periods presented because to do so would be anti-dilutive:
June 30,
20262025
Shares issuable upon exercise of options to purchase Class A Ordinary Shares18,410,564 14,666,538 
Shares issuable upon exercise of Z33 Series Seed Preferred Shares Put Right— 2,000,000 
Shares issuable upon vesting of restricted share units322,892 639,532 
Restricted share awards124,999 249,997 
Total18,858,455 17,556,067